bsm-51415M [Primary Antibody]
STAT1 (1C1) Monoclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Mouse

Target Protein: STAT1

Immunogen Range: 1-200/750


Clonality: Monoclonal

Isotype: IgG1

Entrez Gene: 6772

Swiss Prot: P42224

Source: Purified His-tagged STAT1 protein was used to produced this monoclonal antibody.

Purification: Purified monoclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein G column, followed by dialysis against PBS.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background:

Signal transducer and transcription activator that mediates cellular responses to interferons (IFNs), cytokine KITLG/SCF and other cytokines and other growth factors. Following type I IFN (IFN-alpha and IFN-beta) binding to cell surface receptors, signaling via protein kinases leads to activation of Jak kinases (TYK2 and JAK1) and to tyrosine phosphorylation of STAT1 and STAT2. The phosphorylated STATs dimerize and associate with ISGF3G/IRF-9 to form a complex termed ISGF3 transcription factor, that enters the nucleus. ISGF3 binds to the IFN stimulated response element (ISRE) to activate the transcription of IFN-stimulated genes (ISG), which drive the cell in an antiviral state. In response to type II IFN (IFN-gamma), STAT1 is tyrosine- and serine-phosphorylated. It then forms a homodimer termed IFN-gamma-activated factor (GAF), migrates into the nucleus and binds to the IFN gamma activated sequence (GAS) to drive the expression of the target genes, inducing a cellular antiviral state. Becomes activated in response to KITLG/SCF and KIT signaling. May mediate cellular responses to activated FGFR1, FGFR2, FGFR3 and FGFR4.

Size: 100ul

Concentration: 0.5ug/ul

Predicted Molecular Weight: 87


Cross Reactive Species: Human

For research use only. Not intended for diagnostic or therapeutic use.

VALIDATION IMAGES

Lane 1: HeLa Cell lysates; Lane 2: MCF-7 Cell lysates probed with STAT1 (1141CT26.2.1) Monoclonal Antibody, unconjugated (bsm-51415M) at 1:1000 overnight at 4°C followed by a conjugated secondary antibody for 60 minutes at 37°C.


Lane 1: Human A549 cell lysates; Lane 2: Human Hela cell lysates; Lane 3: Human MCF-7 cell lysates; Lane 4: Human Huvec cell lysates ; Lane 5: Human K562 cell lysates; Lane 6: Human HepG2 cell lysates; Lane 7: Human U87MG cell lysates probed with STAT1 (1C1) Monoclonal Antibody, Unconjugated (bsm-51415M) at 1:1000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.